Idelalisib

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers.[2][1] The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[4][5] It was developed by Gilead Sciences. Idelalisib had annual sales of $168 million (USD) during the year of 2016, up from $132 million (USD) in 2015.[6&a... [wikipedia]